Adenovirus-enhanced receptor-mediated transferrinfection for the generation of tumor vaccines

Cytokines and Molecular Therapy

Volumn 2, Issue 3, 1996, Pages 185-192

  Schweighoffer, Tamas ^a   Berger, Manfred ^a   Buschle, Michael ^a   Schmidt, Walter ^a   Birnstiel, Max L ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

Cancer vaccine; Gene therapy; Interleukin 2; Melanoma

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; INTERLEUKIN 2; INTERLEUKIN RECEPTOR; TUMOR ANTIGEN; TUMOR VACCINE;

ADENOVIRUS; CANCER IMMUNIZATION; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; EXPRESSION VECTOR; GENE TARGETING; MELANOMA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNITY;

ADENOVIRIDAE; ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENE THERAPY; GENETIC VECTORS; HUMANS; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; POLYLYSINE; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TRANSFERRIN;

EID: 0029803048     PISSN: 13556568     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Rous P, An experimental comparison of transplanted tumor and a transplanted normal tissue capable of growth. J Exp Med (1910) 12: 344-65.
2. Prehn RT, Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst (1957) 18: 769-78.
3. Hakomori SI, Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res (1989) 52: 257-31.
4. Rettig WJ, Old LJ, Immunogenetics of human cell surface differentiation. Amni Rev Immtmol (1989) 7: 481-511.
5. Pardoll D, Cancer vaccines. Immunol Today (1993) 14:310-16.
6. Dranoff G, Mulligan RC, Gene transfer as cancer therapy. Adv Immunol (1995) 58: 417-54.
7. Roth C, Rochlitz C, Kourilsky P, Immune response against tumors. Adv Immunol (1994) 57: 281-351.
8. van der Bruggen P, Traversari G, Chômez P et al, A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science (1991) 2: 1643-7.
9. Coulie PG, Brichard V, Van Pel A et al, A new gene coding for a different antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 180: 3542.
10. Wolfel T, Hauer M, Schneider J et al, A pl6INK4ainsensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 269: 1281-4.
11. Mulligan RC, The basic science of gene therapy. Science (1993) 260: 926-32.
12. Wagner E, Zatloukal K, Gotten M et al, Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sei USA (1992) 89: 6099-103.
13. Gotten M, Wagner E, Zatloukal K et al, Highefficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. Proc Natl Acad Sei USA (1992) 89: 6094-8.
14. Fearon ER, Pardoll DM, Itaya T et al, InterIeukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1991) 60: 397-403.
15. Tepper RI, Pattengale PK, Leder P, Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell (1989) 57: 503-12.
16. Tepper RI, Mule JJ, Experimental and clinical studies of cytokine gene-modified tumor cells. Review. Hum Gene 77/er(1994) 5: 153-64.
17. Liu Y, Jones B, Aruffo A et al, Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J Exp Med (1992) 175: 437-45.
18. Ramarathinam L, Castle M, Wu Y, Liu Y, T cell costimulation by B7/BB1 induces CDS T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment and effector function of antitumor T cous. J Exp Med (1994) 179: 1205-14.
19. Cloudman AM, The effect of an extra-chromosomal influence upon transplanted spontaneous tumors in mice. Science (1941) 93: 380-1.
20. Gotten M, Saltik M, Kursa M et al, Psoralen treatment of Adenovirus particles eliminates virus replication and transcription while maintaining the endosomolytic activity of the virus capsid. Virology (1994)205:254-61.
21. Zatloukal K, Schmidt W, Gotten M et al, Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'. Gene (1993) 135: 199-207.
22. van der Bruggen P, Szikora JP, Boel P et al, Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw 1601. Enr jf Immunol (1994) 24: 2134-40.
23. Bubenik J, Simova J, Jandlova T, Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol Lett (1990) 23: 287-92.
24. Cavallo F, Giovarelli M, Gulino A et al, Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol (1992) 149: 3627-35.
25. Bannerji R, Arroyo CD, Cordon-Cardo G, Gilboa E, The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol (1994) 152: 2324-32.
26. Zatloukal K, Schneeberger A, Berger M et al, Elicitation of a systemic and protective anti-melanoma immune response by an IL-2 based vaccine: assessment of critical cellular and molecular parameters. J Immunol (1995) 154: 3406-19.
27. Schmidt W, Schweighoffer T, Herbst E et al, Cancer vaccines: the interleukin 2 dosage effect. Proc Natl AcadSci USA (1995) 92: 4711-14.
28. Dranoff G, Jaffee E, Lazenby A et al, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc NatlAcad Sei USA (1993) 90: 3539-43.
29. Ljunggren G, Ljunggren HG, Dalianis T, T cell subsets involved in immunity against polyoma virusinduced tumors. Virology (1994) 198:714-6.
30. Mackay CR, Marston WL, Dudler L, Naive and memory T cells show distinct pathways of lymphocyte recirculation, j Exp Med (1990) 171: 801-17.
31. Mackay CR, T-cell memory: the connection between function, phenotype and migration pathway. Immunol Today (1991) 12: 189-92.
32. Maass G, Schmidt W, Berger M et al, Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin-2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sei USA (1994) 92: 5540-4.
33. Crab tree GR, Contingent genetic regulatory events in T lymphocyte activation. Science (1989) 243: 355-61.
34. Ebnet K, Chluba-de Tapia J, Hurtenbach U et al, In vivo primed mouse T cells selectively express T cellspecific serine proteinase-1 and the proteinase-like molecules granzyme B and C. lut Immunol (1991) 3: 9-19.
35. Huang AYC, Golumbek P, Ahmadzadeh M et al, Role of bone marrow-derived cells in presenting MHC class-I restricted tumor antigens. Science (1994) 264:961-5.
36. Maass G, Schweighoffer T, Berger M et al, Tumor vaccines: effects and fate of IL-2 transfected murine melanoma cells in vivo, hit J Immunopharmacol (1995) 17: 65-73.
37. Khazaie K, Prifti S, Beckhove P et al, Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. Proc Natl Acad Sei USA (1994) 91: 7430-4.
38. Pober JS, Cotran RS, Cytokines and endothelial cell biology. PhysiolRev (1990) 70: 427-51.
39. Cohen PJ, Cohen PA, Rosenberg SA et al, Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Etir J Immunol (1994) 24: 315-19.
40. Moll H, Fuchs H, Blank C, Rollinghoff M, Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen-specific T cells. Eur J Immtmol (1993) 23: 1595-601.
41. Kaplan G, Walsh G, Guido LS et al, Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med (1992) 175: 1717-28.
42. Larsen CP, Steinman RM, Witmer-Pack M et al, Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med (1990) 172: 1483-93.
43. Earth A, Morton DL, The role of adjuvant therapy in melanoma management. Cancer (1995) 75: 726-34.
44. Earth A, Hoon DS, Foshag LJ et al, Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res (1994) 54: 3342-5.
45. Li Y, McGowan P, Hellstrom I et al, Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma, jf Immitnol (1994) 153: 421-8.
46. Townsend SE, Allison JP, Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 259: 368-70.
47. Chen L, McGowan P, Ashe S et al, Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med (1994) 179:523-32.
48. Yang G, Hellstrom KE, Hellstrom I, Chen L, Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Imimmol (1995) 154: 2794-800.
49. Pan ZK, Ikonomidis G, Lazenby A et al, A recombinant Listeria monocytogeries vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nature Med (1995) 1: 471-7.
50. Thomson SA, Khanna R, Gardner, J et al, Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc NatlAcadSci USA (1995) 92: 5845-9.
51. Pardoll DM, Beckerleg AM, Exposing the immunology of naked DNA vaccines. Immunity (1995) 3: 165-9.
52. Sun WH, Burkholder JK, Sun J et al, In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Natl Acad Sei USA (1995) 92: 2889-93.
53. Peace DJ, Smith JW, Chen W et al, Lysis of Ras oncogene transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated Ras peptide. J Exp Med (1994) 179: 473-9.
54. Kwak LW, Campbell MJ, Czerwinski DK et al, Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med (1992) 327: 1209-15.
55. Tao MH, Levy R, Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature (1993) 363: 755-8.
56. Schweighoffer T et al, Gene Therapy, in press.